Importantly, treatment of USP22-null breast cancer cells did not further reduce the frequency of breast cancer stem cells (Fig. 5D and s5F), supporting the high specificity of this USP22-specific small molecule inhibitor. This evidence concerns the gene USP22 and breast carcinoma.